nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.01.2006 | Original Article

^99mTc-rituximab radiolabelled by photo-activation: a new non-Hodgkin’s lymphoma imaging agent

verfasst von: T. Gmeiner Stopar, I. Mlinaric-Rascan, J. Fettich, S. Hojker, S. J. Mather

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 1/2006

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Rituximab was the first chimeric monoclonal antibody to be approved for treatment of indolent B-cell non-Hodgkin’s lymphoma (NHL). It is directed against the CD20 antigen, which is expressed by 95% of B-cell NHLs. The aim of this study was to explore the possibility of radiolabelling rituximab with ^99mTc for use as an imaging agent in NHL for early detection, staging, remission assessment, monitoring for metastatic spread and tumour recurrence, and assessment of CD20 expression prior to (radio)immunotherapy.

Methods

Rituximab was purified from Mabthera solution (Roche), photo-activated at 302 nm by UV irradiation and radiolabelled with ^99mTc. The effectiveness of the labelling method was evaluated by determination of the number of free thiol groups per photoreduced antibody, radiochemical purity and in vitro stability of ^99mTc-rituximab.

Results

On average, 4.4 free thiol groups per photoreduced antibody were determined. Radiolabelling yields greater than 95% were routinely observed after storage of the photo-activated antibody at −80°C for 195 days. The direct binding assay showed preserved ability of ^99mTc-rituximab to bind to CD20, with an average immunoreactive fraction of 93.3%. The internalisation rate was proven to be low, with only 5.3% of bound ^99mTc-rituximab being internalised over 4 h at 37°C.

Conclusion

Our results demonstrate that ^99mTc-rituximab of high radiochemical purity and with preserved binding affinity for the antigen can be prepared by photoreduction and that the method shows good reproducibility. ^99mTc-rituximab will be further explored as an imaging agent applicable in NHL for the purposes mentioned above.

Golay J, Gramigna R, Facchinetti V, Capello D, Gaidano G, Introna M. Acquired immunodeficiency syndrome-associated lymphomas are efficiently lysed through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by rituximab. Br J Haematol 2002;119:923–9CrossRefPubMed

Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 2005;8:140–74PubMed

Coffey J, Hodgson DC, Gospodarowicz MK. Therapy of non-Hodgkin’s lymphoma. Eur J Nucl Med Mol Imaging 2003;30 Suppl 1:S28–36PubMed

Gopal AK, Press OW. Clinical applications of anti-CD20 antibodies. J Lab Clin Med 1999;134:445–50CrossRefPubMed

Tallman MS. Monoclonal antibody therapies in leukemias. Semin Hematol 2002;39 4:12–9CrossRefPubMed

Withoff S, Bijman MNA, Stel AJ, Delahaye L, Calogero A, de Jonge MWA, et al. Characterization of BIS20x3, a bi-specific antibody activating and retargeting T-cells to CD20-positive B-cells. Br J Cancer 2001;84:1115–21CrossRefPubMed

Avivi I, Robinson S, Goldstone A. Clinical use of rituximab in haematological malignacies. Minireview. Br J Cancer 2003;89:1389–94CrossRefPubMed

Johnson PWM, Glennie MJ. Rituximab: mechanisms and application. Br J Cancer 2001;85 11:1619–23CrossRefPubMed

http://www.emea.eu.int/humandocs/Humans/EPAR/Mabthera/Mabthera.htm. Accessed January 15, 2004

10.

Emmanouilides C. Current status of radioimmunotherapy for non-Hodgkin lymphoma. Haema 2003;6:314–27

11.

Kaminski MS, Zasadny KR, Francis IR, Milik AW, Ross CW, Moon SD, et al. Radioimmunotherapy of B-cell lymphoma with (¹³¹I)anti-B1 (anti-CD20) antibody. N Engl J Med 1993;329:459–65CrossRefPubMed

12.

http://www.rxlist.com/cgi/rxlist.cgi?drug=rituximab. Accessed December 15, 2004

13.

Swerdlow AJ. Epidemiology of Hodgkin’s disease and non-Hodgkin’s lymphoma. Eur J Nucl Med Mol Imaging 2003;30 Suppl 1:S2–12

14.

Hoskin PJ, O’Doherty MJ. Lymphoma: diagnosis and management introduction. Eur J Nucl Med Mol Imaging 2003; 30 Suppl 1:S1CrossRef

15.

Even-Sapir E, Israel O. Gallium-67 scintigraphy: a cornerstone in functional imaging of lymphoma. Eur J Nucl Med Mol Imaging 2003;30 Suppl 1:S65–81PubMed

16.

Hoskin PJ. PET in lymphoma: what are the oncologist’s needs? Eur J Nucl Med Mol Imaging 2003;30 Suppl 1:S37–41CrossRefPubMed

17.

Rankin SC. Assessment of response to therapy using conventional imaging. Eur J Nucl Med Mol Imaging 2003;30 Suppl 1:S56–64PubMed

18.

Sciepers C, Filmont JE, Czernin J. PET for staging of Hodgkin’s disease and non-Hodgkin’s lymphoma. Eur J Nucl Med Mol Imaging 2003;30 Suppl 1:S82–8PubMed

19.

Vinnicombe SJ, Reznek RH. Computerised tomography in the staging of Hodgkin’s disease and non-Hodgkin’s lymphoma. Eur J Nucl Med Mol Imaging 2003;30 Suppl 1:S42–55PubMed

20.

Reske SN. PET and restaging of malignant lymphoma including residual masses and relapse. Eur J Nucl Med Mol Imaging 2003;30 Suppl 1:S82–96PubMed

21.

Spaepen K, Stroobants S, Verhoef G, Mortelamns L. Positron emission tomography with [¹⁸F]FDG for therapy response monitoring in lymphoma patients. Eur J Nucl Med Mol Imaging 2003;30 Suppl 1:S97–105PubMed

22.

Reilly RM. Immunoscintigraphy of tumours using ^99mTc-labelled monoclonal antibodies: a review. Nucl Med Commun 1993;14:347–59PubMed

23.

Mather SJ. Radiolabelled antibodies and peptides. In: Sampson CB, editor. Textbook of radiopharmacy theory and practice. 3rd ed. Amsterdam, The Netherlands: Gordon and Breach Science Publishers; 1990. p. 63–82

24.

Urbain JLC, Vekemans MCM, Lemieux SK, Cosenza SC, Senadhi VK, Milestone BN, et al. Nuclear oncology and the imagine concept. Acta Radiol 1997;38 Suppl 41:21–8

25.

Stalteri MA, Mather SJ. Technetium-99m labelling of the anti-tumour antibody PR1A3 by photoactivation. Eur J Nucl Med 1996;23:178–87CrossRefPubMed

26.

Muddukrishna SN, Chen A, Qi P, Smolenski MA. Quantitation of reduced disulfide groups in monoclonal antibodies using 5-iodoacetamidofluorescein: a novel size exclusion-HPLC technique. Appl Radiat Isotopes 1995;46:1015–26CrossRef

27.

Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 1984;72:77–89CrossRefPubMed

28.

Badger CC, Krohn KA, Bernstein ID. In vitro measurement of avidity of radioiodinated antibodies. Nucl Med Biol 1987;14:605–10

29.

Divgi CR. Status of radiolabeled monoclonal antibodies for diagnosis and therapy of cancer. Oncology 1996;10:939–58PubMed

30.

Juweid ME. Radiotherapy of B-cell non-Hodgkin’s lymphoma: from clinical trials to clinical practice. J Nucl Med 2002;43:1507–29PubMed

31.

Michel RB, Mattes MJ. Intracellular accumulation of the anti-CD20 antibody 1F5 in B-lymphoma cells. Clin Cancer Res 2002;8:2701–13PubMed

32.

Press OW, Farr AG, Borroz KI, Anderson SK, Martin PJ. Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer Res 1989;49:4906–12PubMed

33.

Jilani I, O’Brien S, Manshuri T, Thomas DA, Thomazy VA, Imam M, et al. Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. Blood 2003;102:3514–20CrossRefPubMed

34.

Schaffland AO, Buchegger F, Kosinski M, Antonescu C, Paschoud C, Grannavel C, et al.¹³¹I-rituximab: relationship between immunoreactivity and specific activity. J Nucl Med 2004;45:1784–90PubMed

35.

Scheidhauer K, Wolf I, Baumgartl HJ, Von Schilling C, Schmidt B, Reidel G, et al. Biodistribution and kinetics of¹³¹I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin’s lymphoma. Eur J Nucl Med Mol Imaging 2002;29:1276–82CrossRefPubMed

Titel: 99mTc-rituximab radiolabelled by photo-activation: a new non-Hodgkin’s lymphoma imaging agent
verfasst von: T. Gmeiner Stopar
I. Mlinaric-Rascan
J. Fettich
S. Hojker
S. J. Mather
Publikationsdatum: 01.01.2006
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 1/2006
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-005-1838-4

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2006

Vesico-colic fistula as demonstrated by [18F]FDG-PET

Myocardial ischaemia and metabolic memory

Visualisation of sodium-iodide symporter

18F-FDG PET in the management of endometrial cancer

Quantitative simultaneous 99mTc-ECD/123I-FP-CIT SPECT in Parkinson’s disease and multiple system atrophy

The sentinel lymph node concept. 2005. A.J. Schauer, W. Becker, M. Reiser, K. Possinger (Eds). Springer Verlag, Heidelberg Berlin New York. Hardcover, 565 pp., 420 figs., 228 tables. ISBN 3-540-41041-4. Price €199.95, SFR 338.50, GBP 154.00, US $ 249.00